全球临床研究服务市场－2026-2031年预测

全球临床研究服务市场预计将从 2025 年的 707.24 亿美元成长到 2031 年的 1,095.51 亿美元，复合年增长率为 7.57%。

由于临床试验需求激增，全球临床研究服务市场正在扩张，迫使服务供应商扩大营运规模。研究活动外包提高了效率并缩短了药物研发週期。快速发展的生物製药和生物技术产业对专业临床支援的需求庞大。多方面试验中的国际合作正在推动创新治疗方法的进步。

临床研究服务涵盖临床试验设计、实施和分析所需的各项服务，包括方案製定、病患招募、现场监查、资料管理、统计分析和监管申报。这些服务主要由合约研究组织 (CRO)、学术机构和专业公司提供，对于新药、生物製药和医疗设备的安全性、有效性和合规性评估至关重要。由于试验复杂性的增加、跨境伙伴关係和技术整合，该市场正经历稳定成长，这些因素共同促进了医疗创新并改善了患者的治疗效果。

推动成长要素是对实证医学日益增长的需求，实证医学强调以严谨的科学检验来指导治疗决策、减少实践差异并优化资源配置。将临床研究职能外包给合约研究组织 (CRO) 可以让申办方利用外部专业知识、实现扩充性、控製成本、加快患者招募并确保试验按时合规地进行，同时专注于自身的核心竞争力。在研发投入、技术进步、慢性病发病率上升以及个人化医疗趋势的推动下，生物製药和生物技术产业的扩张正在推动对强大的临床研究基础设施的需求，以支持新型治疗方法的开发。

市场细分反映了服务类型（例如临床数据管理、品质保证、监控）、治疗领域、最终用户（製药/生物技术公司、合约研究组织、学术/研究机构）和地理的多样性。这种结构能够满足各个领域（例如肿瘤学、心臟病学和神经病学）内不同阶段的试验需求和专业需求。

从区域来看，北美占据领先地位，这得益于其先进的医疗基础设施、强大的製药和生物技术生态系统、完善的法规结构以及众多大型合约研究机构（CRO）和研究机构的集中。美国在临床试验和创新方面的大量投资巩固了该地区的领先地位，而欧洲和亚太地区也仍然是重要的贡献者。

主要供应商包括 IQVIA，提供涵盖研究设计、现场管理、患者招募和数据分析的端到端服务；美国实验室控股公司（LabCorp），提供临床试验测试、生物标誌物分析、中心检查室支援和研究管理；Parexel International Corporation，提供包括研究​​通讯协定、数据处理、法规指导和招聘

总体而言，市场正稳步发展，并透过加强试验开展、全球合作和外包专业知识，推动治疗方法的突破，因为相关人员正在应对日益复杂的挑战，以提供更安全、更有效的医疗干预措施。

本报告的主要优势：

• 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
• 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
• 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
• 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
• 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

• 历史资料（2021-2025 年）和预测资料（2026-2031 年）
• 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
• 竞争对手定位、策略和市场占有率分析
• 按业务板块和地区（国家）分類的收入成长和预测分析
• 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 分析范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策和法规
• 策略建议

第四章 技术展望

5. 全球临床研究服务市场（依服务类型划分）

• 介绍
• 临床试验管理服务
• 临床数据管理服务
• 监管服务
• 临床监测服务
• 品管服务
• 生物分析服务
• 其他的

6. 全球临床研究服务市场（依治疗领域划分）

• 介绍
• 肿瘤学
• 循环系统疾病
• 感染疾病
• 神经病学
• 呼吸系统疾病
• 其他的

7. 全球临床研究服务市场（以最终用户划分）

• 介绍
• 製药和生物技术公司
• CRO（委外研发机构）
• 学术和研究机构
• 其他的

8. 全球临床研究服务市场（按地区划分）

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 企业合併、协议、商业合作
• 竞争对手仪錶板

第十章：公司简介

• Iqvia Holdings Inc.
• Pharmaceutical Product Development, Llc（Ppd）
• Parexel International Corporation
• Charles River Laboratories International, Inc.
• Covance Inc.（A Subsidiary Of Laboratory Corporation Of America Holdings）
• Syneos Health Inc.
• Medpace Holdings, Inc.
• Wuxi Apptec Inc.
• Icon Plc

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 分析方法
• 简称

Global Clinical Research Services Market, growing at a 7.57% CAGR, is anticipated to reach USD 109.551 billion in 2031 from USD 70.724 billion in 2025.

The clinical research services market is expanding globally amid surging demand for clinical trials, prompting service providers to scale operations. Outsourcing of research activities is improving efficiency and shortening drug development timelines. The burgeoning biopharmaceutical and biotechnology sectors are generating substantial requirements for specialized clinical support. International collaborations on multifaceted trials are facilitating advancements in innovative therapies.

Clinical research services encompass a comprehensive suite of offerings essential for designing, executing, and analyzing clinical trials, including study protocol development, patient recruitment, site monitoring, data management, statistical analysis, and regulatory submissions. Delivered primarily by contract research organizations (CROs), academic institutions, and specialized firms, these services are indispensable for evaluating safety, efficacy, and compliance of new drugs, biologics, and devices. The market is experiencing steady growth, driven by escalating trial complexity, cross-border partnerships, and technological integration, all contributing to accelerated medical innovation and improved patient outcomes.

Key growth drivers include the mounting demand for evidence-based healthcare, which prioritizes rigorous scientific validation to guide treatments, reduce practice variability, and optimize resource allocation. Outsourcing clinical research functions to CROs enables sponsors to leverage external expertise, achieve scalability, contain costs, expedite recruitment, and maintain focus on core competencies while ensuring timely, compliant trial delivery. Expansion within biopharmaceutical and biotechnology industries-fueled by R&D investments, technological progress, rising chronic disease prevalence, and personalized medicine trends-heightens the need for robust clinical research infrastructure to support novel therapeutic development.

Segmentation reflects diversity by service type (e.g., clinical data management, quality assurance, monitoring), therapeutic area, end-user (pharmaceutical/biotech companies, CROs, academic/research institutions), and geography. This structure accommodates varied trial phases and specialized needs across oncology, cardiology, neurology, and other domains.

Geographically, North America commands the leading share, underpinned by advanced healthcare infrastructure, a dominant pharmaceutical/biotechnology ecosystem, supportive regulatory frameworks, and concentration of major CROs and research entities. Significant U.S. investment in trials and innovation reinforces regional primacy, though Europe and Asia-Pacific remain vital contributors.

Prominent providers include IQVIA, offering end-to-end services spanning study design, site management, patient recruitment, and data analytics. Laboratory Corporation of America Holdings (LabCorp) delivers clinical trial testing, biomarker analysis, central laboratory support, and trial management. PAREXEL International Corporation provides integrated solutions encompassing trial oversight, data handling, regulatory guidance, and recruitment. ICON plc supplies comprehensive capabilities from protocol design and site selection to data administration and submissions.

Overall, the market is advancing at a consistent pace, positioned to catalyze therapeutic breakthroughs through enhanced trial execution, global collaboration, and outsourced expertise, as stakeholders navigate increasing complexity to deliver safer, more effective medical interventions.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Global Clinical Research Services Market Segmentation

• By Service Type
• Clinical Trial Management Services
• Clinical Data Management Services
• Regulatory Services
• Clinical Monitoring Services
• Quality Management Services
• Bioanalytical Services
• Others
• By Therapeutic Area
• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Neurology
• Respiratory Diseases
• Others
• By End-User
• Pharmaceutical And Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic And Research Institutions
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CLINICAL RESEARCH SERVICES MARKET BY SERVICE TYPE

• 5.1. Introduction
• 5.2. Clinical Trial Management Services
• 5.3. Clinical Data Management Services
• 5.4. Regulatory Services
• 5.5. Clinical Monitoring Services
• 5.6. Quality Management Services
• 5.7. Bioanalytical Services
• 5.8. Others

6. GLOBAL CLINICAL RESEARCH SERVICES MARKET BY THERAPEUTIC AREA

• 6.1. Introduction
• 6.2. Oncology
• 6.3. Cardiovascular Diseases
• 6.4. Infectious Diseases
• 6.5. Neurology
• 6.6. Respiratory Diseases
• 6.7. Others

7. GLOBAL CLINICAL RESEARCH SERVICES MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical And Biotechnology Companies
• 7.3. Contract Research Organizations (Cros)
• 7.4. Academic And Research Institutions
• 7.5. Others

8. GLOBAL CLINICAL RESEARCH SERVICES MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Iqvia Holdings Inc.
• 10.2. Pharmaceutical Product Development, Llc (Ppd)
• 10.3. Parexel International Corporation
• 10.4. Charles River Laboratories International, Inc.
• 10.5. Covance Inc. (A Subsidiary Of Laboratory Corporation Of America Holdings)
• 10.6. Syneos Health Inc.
• 10.7. Medpace Holdings, Inc.
• 10.8. Wuxi Apptec Inc.
• 10.9. Icon Plc

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations